Induction of apoptosis by HAC-Y6, a novel microtubule inhibitor, through activation of the death receptor 4 signaling pathway in human hepatocellular carcinoma cells

Oncology Reports

Volumn 24, Issue 5, 2010, Pages 1169-1178

  Tsai, Jui Ying ^a   Hung, Chao Ming ^b   Bai, Shih Ting ^a   Huang, Chi Hung ^c   Chen, Wei Chih ^a   Chung, Jinh Gung ^a   Kuo, Sheng Chu ^a   Way, Tzong Der ^a   Huang, Li Jiau ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b I SHOU UNIVERSITY   (Taiwan)

^c Taiwan Advance Biopharm Inc ^*  (Taiwan)

Author keywords

Death receptor 4; HAC Y6; Hepatocellular carcinoma cells; Microtubule inhibitor; p38

Indexed keywords

6 ACETYL 9 (3,4,5 TRIMETHOXYBENZYL) 9H PYRIDO[2,3 B]INDOLE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CASPASE 9; COLCHICINE; DEATH RECEPTOR 4; PROTEIN BAX; PROTEIN BID; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL VIABILITY; CONTROLLED STUDY; DEPOLYMERIZATION; DRUG DEVELOPMENT; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO SELECTION; LIVER CELL CARCINOMA; MALE; MICROTUBULE ASSEMBLY; MITOSIS SPINDLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

EID: 78149330162     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000969     Document Type: Article

References (42)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
3. Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003.
4. Kirschner MW: Microtubule assembly and nucleation. Int Rev Cytol 54: 1-71, 1978.
5. Wittmann T, Hyman A and Desai A: The spindle: a dynamic assembly of microtubules and motors. Nat Cell Biol 3: E28-E34, 2001.
6. Sudakin V and Yen TJ: Targeting mitosis for anti-cancer therapy. Bio Drugs 21: 225-233, 2007.
7. Pellegrini F and Budman DR: Review: tubulin function, action of antitubulin drugs and new drug development. Cancer Invest 23: 264-273, 2005.
8. Schiff PB and Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565, 1980.
9. Cotter TG: Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 9: 501-507, 2009.
10. Fulda S and Debatin KM: Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25: 4798-4811, 2006.
11. Chakraborty DP, Barman BK and Bose PK: On the structure of girinimbine, a pyranocarbazole derivative isolated from Murraya koenigii Spreng. Sci Cult 30: 445, 1964.
12. Ramsewak RS, Nair MG, Strasburg GM, DeWitt DL and Nitiss JL: Biologically active carbazole alkaloids from Murraya koenigii. J Agric Food Chem 47: 444-447, 1999.
13. Ito C, Itoigawa M, Nakao K, Murata T, Tsuboi M, Kaneda N and Furukawa H: Induction of apoptosis by carbazole alkaloids isolated from Murraya koenigii. Phytomedicine 13: 359-365, 2006.
14. Ito C, Itoigawa M, Sato A, Hasan CM, Rashid MA, Tokuda H, Mukainaka T, Nishino H and Furukawa H: Chemical constituents of Glycosmis arboera: three new carbazole alkaloids and their biological activity. J Nat Prod 67: 1488-1491, 2004.
15. Itoigawa M, Kashiwada Y, Ito C, Furukawa H, Tachibana Y, Bastow KF and Lee KH: Antitumor agents. 203. Carbazole alkaloid murrayaquinone A and related synthetic carbazole-quinones as cytotoxic agents. J Nat Prod 63: 893-897, 2000.
16. Ito C, Katsuno S, Itoigawa M, Ruangrungsi N, Mukainaka T, Okuda M, Kitagawa Y, Tokuda H, Nishino H and Furukawa H: New carbazole alkloids from Clausena anisata with antitumor promoting activity. J Nat Prod 63: 125-128, 2003.
17. Lee JC, Tsai CY, Kao JY, Kao MC, Tsai SC, Chang CS, Huang LJ, Kuo SC, Lin JK and Way TD: Geraniin-mediated apoptosis by cleavage of focal adhesion kinase through upregulation of Fas ligand expression in human melanoma cells. Mol Nutr Food Res 52: 655-663, 2008.
18. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K and Cobb MH: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22: 153-183, 2001.
19. Saklatvala J, Rawlinson L, Waller RJ, Sarsfield S, Lee JC, Morton LF, Barnes MJ and Farndale RW: Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue. J Biol Chem 22: 6586-6589, 1996.
20. Lee CY, Kuo SC, Teng CM and Huang LJ: Synthesis and anti-platelet activity of 9-benzyl-3-hydroxymethylcarbazoles. Chin Pharm J 54: 25-34, 2002.
21. Lee CY, Huang LJ, Wang JP and Kuo SC: Anti-inflammatory activity of 9-substituted benzyl-3-substituted carbazole derivatives. Chin Pharm J 54: 35-40, 2002.
22. Ho FM, Kang HC, Lee ST, Chao Y, Chen YC, Huang LJ and Lin WW: The anti-inflammatory actions of LCY-2-CHO, a carbazole analogue, in vascular smooth muscle cells. Biochem Pharmacol 74: 298-308, 2007.
23. Hui KM: Human hepatocellular carcinoma: expression profiles based molecular interpretations and clinical applications. Cancer Lett 10: 1-7, 2008.
24. Shi YQ, Zhu CJ, Yuan HQ, Li BQ, Gao J, Qu XJ, Sun B, Cheng YN, Li S, Li X and Lou HX: Marchantin C, a novel microtubule inhibitor from liverwort with anti-tumor activity both in vivo and in vitro. Cancer Lett 276: 160-170, 2009.
25. Wang SW, Pan SL, Huang YC, Guh JH, Chiang PC, Huang DY, Kuo SC, Lee KH and Teng CM: CHM-1, a novel synthetic quinolone with potent and selective antimitotic antitumor activity against human hepatocellular carcinoma in vitro and in vivo. Mol Cancer Ther 7: 350-360, 2008.
26. Meraldi P, Draviam VM and Sorger PK: Timing and checkpoints in the regulation of mitotic progression. Dev Cell 7: 45-60, 2004.
27. Fesik SW: Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5: 876-885, 2005.
28. Ghobrial IM, Witzig TE and Adjei AA: Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 55: 178-194, 2005.
29. Putcha GV, Harris CA, Moulder KL, Easton RM, Thompson CB and Johnson EM Jr: Intrinsic and extrinsic pathway signaling during neuronal apoptosis: lessons from the analysis of mutant mice. J Cell Biol 157: 441-453, 2002.
30. Saelens X, Festjens N, Vande Walle L, van Gurp M, van Loo G and Vandenabeele P: Toxic proteins released from mitochondria in cell death. Oncogene 23: 2861-2874, 2004.
31. Brenner C and Kroemer G: Apoptosis: mitochondria - the death signal integrators. Science 289: 1150-1151, 2000.
32. Lavrik I, Golks A and Krammer PH: Death receptor signaling. J Cell Sci 118: 265-267, 2005.
33. Kabore AF, Sun J, Hu X, McCrea K, Johnston JB and Gibson SB: The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis 11: 1175-1193, 2006.
34. Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB, Nesterov A and Kraft AS: The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 22: 4953-4963, 2003.
35. Wagner EF and Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9: 537-549, 2009.
36. Deacon K, Mistry P, Chernoff J, Blank JL and Patel R: p38 mitogen-activated protein kinase mediates cell death and p21-activated kinase mediates cell survival during chemotherapeutic druginduced mitotic arrest. Mol Biol Cell 14: 2071-2087, 2003.
37. Holmes WF, Soprano DR and Soprano KJ: Early events in the induction of apoptosis in ovarian carcinoma cells by CD437: activation of the p38 MAP kinase signal pathway. Oncogene 22: 6377-6386, 2003.
38. Losa JH, Parada Cobo C, Viniegra JG, Sánchez-Arevalo Lobo VJ, Ramón y Cajal S and Sánchez-Prieto R: Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene 22: 3998-4006, 2003.
39. Frey RS and Singletary KW: Genistein activates p38 mitogen-activated protein kinase, inactivates ERK1/ERK2 and decreases Cdc25C expression in immortalized human mammary epithelial cells. J Nutr 133: 226-231, 2003.
40. Lavelle D, DeSimone J, Hankewych M, Kousnetzova T and Chen YH: Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway. Leuk Res 27: 999-1007, 2003.
41. Wang X, McGowan CH, Zhao M, He L, Downey JS, Fearns C, Wang Y, Huang S and Han J: Involvement of the MKK6-p38gamma cascade in gamma-radiation-induced cell cycle arrest. Mol Cell Biol 20: 4543-4552, 2000.
42. Zhang Z, Leonard SS, Huang C, Vallyathan V, Castranova V and Shi X: Role of reactive oxygen species and MAPKs in vanadate-induced G(2)/M phase arrest. Free Rad Biol Med 34: 1333-1342, 2003.